SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer

NCT02299999 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

1460

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Breast Cancer

Interventions

DRUG: AZD2014
DRUG: AZD4547
DRUG: AZD5363
DRUG: AZD8931
DRUG: Selumetinib
DRUG: Vandetanib
DRUG: Bicalutamide
DRUG: Olaparib
DRUG: Anthracyclines
DRUG: Taxanes
DRUG: cyclophosphamide
DRUG: DNA intercalators
DRUG: Methotrexate
DRUG: vinca alkaloids
DRUG: Platinum based chemotherapies
DRUG: Bevacizumab
DRUG: Mitomycin C
DRUG: Eribulin
DRUG: MEDI4736

Sponsor

UNICANCER

Collaborators

[object Object]
[object Object]